>> WE ARE TRACKING THE KEY PLAYERS, THE MAJOR MOVES, AND THE CAPITAL FLOWS SHAPING GLOBAL MARKETS. THIS IS "BLOOMBERG DEALS." DANI: WELCOME TO ANOTHER EPISODE OF "BLOOMBERG DEALS." DEDICATED TO CORPORATE ACTION RESHAPING MARKETS AND WELCOME TO THE SECOND QUARTER AFTER THE BEST QUARTER EVER FOR M&A. TODAY, READY FOR TAKEOFF, WE LEARN LESS THAN AN HOUR AGO FROM BLOOMBERG NEWS SPACEX HAS FILED CONFIDENTIALLY FOR AN IPO.THE COMPANY IS ONE STEP CLOSER TO DELIVERY THE BIGGEST EVER LISTING. MY EXCLUSIVE CONVERSATI ...

MATT: 30 MINUTES TILL THE START OF THE CASH TRADE, FUTURES ARE HIGHER AGAIN. "BLOOMBERG OPEN INTEREST" STARTS NOW. MATT: PRESIDENT PRESIDENT DELIVERS A PRIMETIME SPEECH IS UP WITH SOME OF THE ROSE PARADE POSTAL RATE MECHANICAL DMV'S ROLE IN IRAN. DANI: RETAILER ISSUE FOR SURPRISING ME OUT HERE'S THE SLIDING SIDE HEADWINDS. MATT: OPENAI RAISES SUPPORT AROUND YET EVALUATION CAME TO 850 2 BILLION IN TOTAL. DANI: ANOTHER PIECE ON SOME OTHER TECH MOVERS. " INTEL AND APOLLO ARE DOING BECAUSE BECAUSE THIS IS A DEA ...

Flash | 31 Mar 2026 11:29:25 ET │ 10 pages CMOC (3993.HK) Takeaways from Chairman Meetings after FY25 Results CITI'S TAKE Jimmy Feng, CFAAC +852-2501-7588 jimmy.feng@citi.com We hosted meetings with CMOC after its FY25 results in HK on 31st Mar. Mr. Liu Jianfeng, Chairman and CIO, Mr. Xu Hui, Board Secretary, and Ms. Laura Zhang, IR Director, presented at meetings. The unit sulfur consumption is ~1t sulfur per ton of copper output, and CMOC purchases sulfur from traders that sourcing sulfur from various reg ...

Biogen Business Update Call Summary Company and Industry Overview - **Company**: Biogen - **Acquisition Target**: Apellis Pharmaceuticals - **Industry**: Biotechnology, specifically focusing on immunology and rare diseases Key Points and Arguments Acquisition Rationale - Biogen is acquiring Apellis for approximately **$5.6 billion** in cash, with an additional contingent value tied to sales performance of Apellis' products [20][21] - The acquisition aligns with Biogen's strategy to expand beyond neuroscience into immunology and rare diseases, enhancing its growth portfolio [5][14] - Apellis' products, **Syfovre** and **Empaveli**, are seen as best-in-class therapies addressing significant unmet needs in immune-mediated retinal disease and rare hematology [14][15] Product Insights - **Syfovre**: First FDA-approved therapy for Geographic Atrophy, targeting a market of **1.5 million** diagnosed patients in the U.S., with less than **10%** currently treated [15][30] - **Empaveli**: Approved for PNH and two rare kidney diseases (C3G and ICMPGN), with significant growth potential as it is the only FDA-approved therapy for these conditions [16][17] - Biogen expects combined revenue growth from these products in the **mid- to high teens** percentage range over the next two years [21][22] Strategic Fit and Market Position - The acquisition is viewed as a strategic fit, enhancing Biogen's capabilities in nephrology and immunology, with a focus on leveraging Apellis' established commercial infrastructure [19][22] - Biogen aims to utilize Apellis' sales and marketing team to accelerate the launch of its own pipeline product, **felzartamab**, in kidney disease [19][22] Financial Considerations - The acquisition will be financed through cash on hand, revolver borrowings, and a bank term loan, with expected financing costs of **$120 million-$130 million** in 2026 and 2027 [20] - Biogen anticipates being able to repay the acquisition-related debt by the end of **2027**, maintaining strategic flexibility [20][23] - The deal is expected to be accretive starting in **2027**, significantly increasing Biogen's non-GAAP diluted EPS CAGR through the end of the decade [23] Competitive Landscape - Biogen acknowledges the competitive nature of the markets for both Syfovre and Empaveli, with ongoing investments from competitors like Astellas and Novartis [30][31] - Despite competition, Biogen believes Syfovre has a competitive advantage due to its best-in-class profile and the potential for increased patient engagement [30][31] Risks and Challenges - Potential risks include variability in patient activation and retention rates, particularly for Syfovre, where **50%** of patients may drop off treatment [45][66] - Long-term forecasts for both products are subject to uncertainties in epidemiology and market dynamics, particularly for IC-MPGN [66] Future Outlook - Biogen remains committed to its neuroscience portfolio while strategically expanding into immunology and rare diseases [81][84] - The company plans to update its full-year **2026** financial guidance in the upcoming earnings report [24] Additional Important Insights - The acquisition process involved extensive market research and due diligence, ensuring alignment with Biogen's strategic goals [25][70] - Biogen's leadership emphasizes the importance of patient education and engagement to improve treatment adherence and market penetration for both products [45][46] - The integration of Apellis' team is expected to enhance Biogen's capabilities in nephrology and support the launch of future products [19][90]

Molson Coors logo displayed with Coors Light bottles, representing brewing giant amid takeover speculation in beverage industry. Key Points The recent acquisition of a popular cocktail brand highlights the company's successful strategic expansion beyond its traditional beer portfolio. Several key financial metrics suggest that Molson Coors is fundamentally undervalued, making it an attractive opportunity for discerning investors. Recent share purchases by company insiders signal strong confidence in ...

Bank of America (NYSE:BAC) has launched a Private Capital M&A Group to help private equity firms offload companies more efficiently.The group, which is co-headed by Richard Peacock and Amanda Dupuy Ugarte, will work across BoFA's teams to assist private equity firms in monetizing their portfolio companies, Bloomberg reported.Peacock will also continue to lead the consumer and retail M&A and Dupuy Ugarte will continue working in global secondary advisory investment banking. The two will also work with Zeesha ...

German consumer brand Henkel announced Thursday that it has agreed to acquire all of prestige haircare brand Olaplex for $1.4 billion.The company said the deal, at an offer price of $2.06 per share, was unanimously approved by Olaplex's board of directors and marks an "important milestone" in Henkel's business strategy."The planned acquisition of OLAPLEX is fully in line with Henkel's strategy to expand its portfolio through compelling, value-adding M&A activities," Henkel CEO Carsten Knobel said in a state ...

Core Insights - Banijay Group has successfully executed a strategic roadmap, significantly enhancing its position in the entertainment industry through two transformative acquisitions: Tipico Group and the merger with All3Media [2][4][15] - The company anticipates reaching approximately €10 billion in revenue by 2029, driven by a robust growth trajectory and strategic synergies [5][11] Financial Performance - Proforma revenue for the new group is projected at €7.4 billion, with an adjusted EBITDA of €1.6 billion and adjusted free cash flow of €1.2 billion [5] - The company aims for a mid-to-high single-digit growth in adjusted EBITDA for 2026, with an expected cash flow conversion rate of around 80% [8][10] Strategic Roadmap - The strategic roadmap for 2026-2029 focuses on three key drivers: sustained organic growth, development of synergies across business segments, and disciplined consolidation within core activities [11][12] - The company is positioned to capitalize on major industry trends, aiming for around €10 billion in revenues by 2029 [13] Shareholder Value - Banijay Group plans to distribute an exceptional €400 million dividend post-closing of the All3Media operation, subject to AGM approval [6] - The company targets a progressive dividend increase of over 10% CAGR from 2025 to 2029, alongside a solid deleveraging strategy aiming for a leverage ratio of approximately 2x by 2029 [10][14] Market Positioning - The acquisition of Tipico Group enhances Banijay's sports betting and gaming activities, expected to generate around €100 million in synergies [15] - The merger with All3Media strengthens Banijay's content production and distribution capabilities, positioning it among the leading independent players globally [15]

Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors. One executive’s patent cliff is another executive’s lucrative exit. German pharmaceutical giant Merck revealed Wednesday that it’s paying $6.7 billion for Terns Pharmaceuticals, as it tries to bridge a multibillion-dollar gap when its bestselling Keytruda comes off patent. Sign up for The Daily Upside at no cost for premium analysis on all your favorite stocks. READ ALSO: Lawsuit Losing S ...

For the full fiscal year, Koblinski said Karman delivered record results, with revenue and adjusted EBITDA ahead of the updated guidance provided roughly two months earlier. Full-year revenue was $472 million , gross profit was $190 million (40% of revenue), and adjusted EBITDA was $145 million .Koblinski said the company delivered “another quarter of record performance,” driven by execution and momentum following Karman’s February 2025 IPO. For the fourth quarter, he reported record quarterly revenue of $1 ...